• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Piper Sandler resumed coverage on CytomX Therapeutics with a new price target

    4/14/25 8:16:21 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTMX alert in real time by email
    Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously
    Get the next $CTMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTMX

    DatePrice TargetRatingAnalyst
    4/14/2025$3.25 → $2.50Overweight
    Piper Sandler
    5/28/2024$2.25 → $3.50Neutral → Overweight
    Piper Sandler
    5/9/2024$8.00Neutral → Outperform
    Wedbush
    5/6/2024$2.50 → $8.00Hold → Buy
    Jefferies
    4/22/2024Underweight → Neutral
    JP Morgan
    11/14/2022$3.00 → $2.60Outperform → Market Perform
    BMO Capital Markets
    7/7/2022$16.00 → $4.00Buy → Neutral
    Mizuho
    7/7/2022$10.00 → $1.50Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on CytomX Therapeutics with a new price target

      Piper Sandler resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $2.50 from $3.25 previously

      4/14/25 8:16:21 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously

      5/28/24 7:31:35 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics upgraded by Wedbush with a new price target

      Wedbush upgraded CytomX Therapeutics from Neutral to Outperform and set a new price target of $8.00

      5/9/24 7:20:16 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Financials

    Live finance-specific insights

    See more
    • CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

      SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to j

      5/5/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

      - Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Maintained financial strength with cash runway into Q2 2026 - - Company to host conference call today at 2 p.m. PST / 5 p.m. EST - SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced 2024 financial results and provided a business update. "Throughout 202

      3/6/25 4:10:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minut

      2/27/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Leadership Updates

    Live Leadership Updates

    See more
    • CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an

      3/21/24 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie

      7/17/23 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s

      4/14/22 4:15:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CTMX
    SEC Filings

    See more
    • CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

      SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May 12, 2025, before the open of the U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to j

      5/5/25 8:00:00 AM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

      SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in collaboration with Moderna on an mRNA encoded masked IL-12 molecule. The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, being held in Chicago, IL on April 25-30, 2025. "We are excited to share new preclinical data at AACR, establishing proof of concept for an mRNA encoded masked molecule in the treatment of cancer," said Marcia Belvin, Ph.D. SVP, Chief Scientific Officer of CytomX Therapeutics. "IL-12 has shown promising anti-tumor a

      4/28/25 4:00:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

      - Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Maintained financial strength with cash runway into Q2 2026 - - Company to host conference call today at 2 p.m. PST / 5 p.m. EST - SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced 2024 financial results and provided a business update. "Throughout 202

      3/6/25 4:10:00 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by CytomX Therapeutics Inc.

      DEFA14A - CytomX Therapeutics, Inc. (0001501989) (Filer)

      4/28/25 4:17:15 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by CytomX Therapeutics Inc.

      DEF 14A - CytomX Therapeutics, Inc. (0001501989) (Filer)

      4/28/25 4:15:40 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by CytomX Therapeutics Inc.

      S-8 - CytomX Therapeutics, Inc. (0001501989) (Filer)

      3/6/25 4:06:14 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Mccarthy Sean A. sold $22,556 worth of shares (37,656 units at $0.60), decreasing direct ownership by 4% to 995,195 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:34:40 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Ogden Christopher sold $5,122 worth of shares (8,551 units at $0.60), decreasing direct ownership by 4% to 201,026 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:33:49 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Chu Yu-Waye sold $2,411 worth of shares (4,025 units at $0.60), decreasing direct ownership by 3% to 135,725 units (SEC Form 4)

      4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

      3/20/25 4:32:56 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:26:32 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 4:00:06 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

      SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

      11/14/24 3:03:21 PM ET
      $CTMX
      Biotechnology: Pharmaceutical Preparations
      Health Care